4 Marijuana Stocks To Watch This Week

The Horizons’ Marijuana Life Sciences ETF (HMMJ) (HMLSF) is the largest and most representative marijuana exchange traded fund in the markets. The fund strives to duplicate, to an extent, the performance of the North American Marijuana Index (NAMI). The NAMI was designed to track the performance of a basket of North American life sciences companies with a focus of their operations in the marijuana industry.

marijuana.jpg

Marijuana stocks, for the most part, have started the year off on a strong note as this marijuana ETF has risen 45% year to date.  As lawmakers advocate for legislative changes in favor of marijuana legalization and the adoption of marijuana for medical purposes rises, the sector has responded favorably.  Investors seeking opportunities in th budding  marijuana sector may benefit from keeping tabs on several marijuana stocks.

Leafbuyer Technologies, Inc. (LBUY), a leading cannabis technology and marketing platform that connects consumers to dispensaries and product companies, announced that its quarterly cash sales growth rose 36% year over year in the quarter ending March 31, 2019. The company attributes this success to mainly to platform enhancements, order ahead and Leafbuyer loyalty as well as a multi-state sales team.  The company’s go forward plan is to continue to expand into newly legal US markets, while increasing consumer retention to boost bottom line revenues.

“This growth provides momentum and a solid foundation for 2019. As we increase our national footprint and expand our industry leading platform, we’re forecasting significant sales gains through the remainder of the year,” said Kurt Rossner, CEO.

Last month. Leafbuyer announced that the number of its Greenlight platform users has reached nearly 80,000.  The platform allows consumers to order cannabis products ahead, earn loyalty points, and cut the line to pick up and pay at participating dispensaries. At the time of this news release, the number of Leafbuyer dispensary clients with capabilities grew to 60 dispensaries, located throughout the states of California, Colorado, Oklahoma, and Michigan.

Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the health & wellness, announced that it has been working to resolve its 9.5% convertible notes due April 2019 and intends to repay the notes with cash from a business transaction as well as the net proceeds of a planned equity investment from long-term investor Foris Ventures.

“We are pleased with the support of our long term investors in supporting our plans to pay off this debt,” said John Melo, Amyris President and CEO. “We believe this pathway toward retiring our April 2019 debt should mitigate some of the dilutive impact on equity and we will provide more details and an update when this process is complete.”

At the end of March, Amyris announced stated it will discuss at an April 15 conference its previously disclosed cannabinoid development, licensing and commercialization agreement containing $300 million of R&D and milestone payments and a long-term royalty stream. Since, the company reached its first milestone for its cannabinoid partner, LAVVAN. They brought in the first payment of $10 million, which is part of a $300 million collaboration before future royalty payments.

Aphria Inc. (APHA) , a leading global cannabis company, announced fiscal third-quarter earnings reporting a loss as the company booked a C$58 million impairment charge and an additional C$30 million in operating losses. For the quarter ended Feb. 28th, Aphria reported a loss of $0.20 per share, compared to earnings of $0.08 per share for the year earlier.  However, the company reported that total revenue grew by 617% to $73.6 million compared to the $10.3 million the year prior.

“Our organization has experienced significant change in a very short period of time which was necessary to propel the Company forward. Aphria will continue to drive sustainable long-term shareholder value by leveraging its strong brand positioning, superior distribution model, product innovation, industrial scale cultivation and automation, medical-use leadership and strategic global platform” stated Irwin D. Simon, Chairman and Interim CEO.

The company also provided an update that it has entered into a series of transactions that will accelerate the expiration of an unsolicited takeover offer from Green Growth Brands to April 25. The transactions will provide up to an additional $89 million of liquidity without dilution to shareholders, according to the company.

Aurora Cannabis Inc. (ACB), a world leading cannabis company, provided an update on the status of Aurora Sun, the company’s latest and largest Sky Class facility which is currently under construction in Alberta. Aurora Sun will now be expanded by 33% from its original plans totaling to 1.62 million square feet to meet consumer demands. Aurora projects an expected production capacity at Aurora Sun in excess of 230,000 kg of high-quality cannabis annually.

“Aurora Sun represents the next evolution in our Sky Class facility design, delivering massive scale, low cost production, and consistent, high-quality cannabis,” said Terry Booth, CEO. “The increased scale of Aurora Sun reflects our expectations for the long-term growth in global demand, especially the higher margin international medical markets which will be faced with significant supply shortages for the foreseeable future. Sun is also designed with flexibility in mind to enable us to quickly meet changing market demands, particularly as breeding and cultivation technologies evolve and as customer preferences and requirements change.”

cannabisstocks1.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018, and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam has been compensated an additional $100,000 by Leafbuyer Technologies for a period of coverage from April 12, 2019 to June 12, 2019. Midam may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc.. Click here for full Midam disclaimer.

Advertisements

4 Healthcare Stocks To Focus On Today

The global healthcare market is forecast to hit $53.65 billion by 2025, according to a report by Grand View Research. There are several factors accountable for driving the growth of the healthcare industry such as the reduction of healthcare spending among hospitals and providers, improved technology and the rising use of data-enriched products like mHealth, eHealth, Electronic Health Records and mobile apps.

healthcarestocks.jpg

Multi-Trillion Dollar Industry Providing Massive Opportunity In 2019 & Beyond 

The report detailed, “with the combination of artificial and human intelligence data analytics, which offer wide opportunities to further customize medical approaches, the demand for these tools is anticipated to increase over the forecast period”.

Healthcare companies seeking to develop innovative and effective solutions to advance the quality of care could catalyze opportunities for investors looking to healthcare stocks.

Premier Health Group (PHGRF) (PHGI.CN)a company focused on innovative healthcare approaches that combine human skill-based expertise with emerging technologies, announced that further to its previous news release, it has entered into a share purchase agreement to acquire two cash flow positive Metro Vancouver pharmacies. The pharmacies had combined annual revenue of approximately $6 million for the fiscal year ended August 31, 2018, and Premier Health expects to complete the acquisition during Q2 2019.

“We are very excited about this opportunity to acquire two well-run and profitable pharmacies.  As part of our patient centric model, fill and fulfillment is a major component of our telemedicine app.  We are also pleased to have the pharmacies’ key management team, with over 20 years’ of combined experience managing pharmacies, come on board to continue running operations. In light of our recent announcement of our medical cannabis decision tool for our JUNO EMR clients, our pharmacists will be able to help with patient education and support regarding medical cannabis” said Dr. Essam Hamza, CEO. “In addition, with one of the pharmacies occupying a space of over 6,000 square feet, we have the potential to open a new medical and/or cannabis clinic within the existing space.”

This news followed the announcement that the company has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support (CDS) tool to provide Premier Health’s over 4600 physicians using its Juno EMR platform access to the industry’s sole medical cannabis-specific CDS tool. Premier Health has also recently partnered with Bio Conscious Technologies (BCT) to bring their artificial intelligence (AI) technology to Premier Health’s user base for improved monitoring and management of chronic conditions, such as diabetes.

Avinger, Inc. (AVGR), a commercial stage medical device company, announced that it has received 510(k) clearance from the U.S. FDA for its Pantheris SV (Small Vessel) image-guided atherectomy system, a product line extension of its Lumivascular image-guided atherectomy platform.  The Pantheris SV device is designed for the diagnosis and treatment of Pulmonary Artery Disease (PAD) in small vessels, 2 to 4 millimeters in diameter, with its lower profile and longer length.

“We are excited to receive U.S. pre-marketing clearance for Pantheris SV, which we believe could expand our addressable market for atherectomy procedures by as much as 50%,” said Jeff Soinski, Avinger’s President and CEO. “With the clearance of this new device, we are well-positioned to build on the positive momentum we have seen in our Pantheris business since the introduction of the next-generation system in 2018. Following our anticipated limited launch of Pantheris SV, we plan on leveraging our growing commercial infrastructure and installed base of Lumivascular accounts to efficiently scale up the introduction of Pantheris SV and drive growth of our Pantheris product family in the second half of 2019.”

Back in October, the device received CE Marking and the first patients were treated with the device in Germany in November.  Avinger plans to have a limited launch of the device in several U.S. sites when commercial product is available.  According to the company, this new device is expected to increase the available market for the company up to 50%.

Precipio, Inc. (PRPO), a specialty diagnostics company, announced that it is negotiating a definitive agreement with a manufacturer to produce its patented IV-Cell media.  According to the company, the manufacturing partner comes with experience and large volume manufacturing capabilities.  Furthermore, it has the embedded quality-control processes, and the various ISO-related certifications required to mass-produce the media for global distribution.

“This is an exciting time for us, as we move towards the start of commercializing the technologies we’ve developed,” said Ilan Danieli, CEO. “The company and its shareholders deserve to reap the benefits of the innovative products developed, as we translate ideas in the laboratory into products – and revenue, for the company.”

This news followed the announcement of Methodist Hospital, of Memphis, TN, selecting Precipio’s HemeScreen assay for use in its molecular hematology testing laboratory. HemeScreen’s average turnaround time is 2- 4 days, compared to 2 weeks. According to the company, this deal may generate between $50-100K in revenue annually.

Hemispherx Biopharma, Inc.  (HEB), an immuno-pharma R&D and emerging commercial growth company, announced the first participant received initial dosing in its clinical trial sponsored by Roswell Park Comprehensive Cancer Center evaluating the company’s experimental drug Ampligen® (rintatolimod) in combination with Merck’s Keytruda® (pembrolizumab) for the treatment of metastatic triple-negative breast cancer.

“We are very excited to see the first patient treated as part of this important clinical trial evaluating Ampligen in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. We could not ask for better partners than the world-class team at Roswell Park Comprehensive Cancer Center, as we seek to evaluate the impact of the combined therapy on this high risk and very sick patient population,” said CEO Thomas K. Equels.

“Our extensive work with Ampligen has led many top oncologists to conclude, including in peer reviewed medical journal articles, that Ampligen has the potential to change the tumor microenvironment. Making tumors easier targets for checkpoint blockade therapies creates an exciting new approach with the potential to significantly improve clinical outcomes for patients in multiple solid tumor cancer types.”

biotechstocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. Midam owns zero shares of Premier Health Group Inc., which they purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Today’s Trending Cannabis Stocks

The cannabis industry is projected to grow to $50 billion by 2029 from $17 billion in 2019, according to analyst firm Jefferies.  The firm’s estimate includes the Canadian markets, the United States’ thirty-three medicinal markets and seventeen recreational markets, Europe’s twelve-country medical market, Latin America’s five-country medical and 2-country recreational market as well as three other countries with a legal medical market.

cannabisstocks.jpg

Jefferies analyst Owen Bennett, Jefferies analyst believes that the firm’s projection is “probably conservative,” and that a “realistic upside scenario” may be a global cannabis market as large as $130 billion by 2029. “This assumes full U.S. federal legalization, full recreational and medical legalization across Europe, full medical and recreational legalization across Lat Am, and cannabis disruption of a number of other industries,” Bennett added.

While the cannabis industry continues to show strength and sentiment surrounding stocks in the sector remains positive, investors may continue to find opportunities in cannabis stocks.

ParcelPal Technology Inc. (PTNYF) (PKG) (FSE: PT0), a technology-driven logistics company purposed with connecting consumers to the goods they love within an hour, announced it will be hosting an investor update conference call on May 17th, 2019 to review recent progress. The company also announced that it will be releasing its quarterly financial statements for Q4 FY2018 by April 30, 2019.

This followed the news of achieving a major milestone, the completion of over 2 million deliveries.  The company’s plans to move forward include more joint ventures, expansion on its technology and to push its platform on multiple consumer verticals, while expanding operations across Canada and into the U.S. ParcelPal is in the final stages of launching medical and recreational cannabis delivery in Canada with Choom Holdings (CHOOF) and recently signed Kiaro.  This on-demand cannabis delivery plan is expected to begin in April 2019, with more details to follow, and is expected to drive additional users to the platform and open fresh markets.

President and CEO Kelly Abbott states, “We are extremely excited to have achieved this major milestone. Our growth in 2018 was tremendous and our team has grown significantly. We are looking forward to a successful rollout in the cannabis industry amongst other verticals in the coming months across Canada with existing and future partnerships.”

Aurora Cannabis Inc. (ACB) announced that the company has appointed Carey Squires as its Executive Vice President of Corporate Development and Strategy. In this newly created role, reporting to the Executive Chairman, Mr. Squires in collaboration with senior executives across

“With deep experience in the U.S. and Canadian capital markets, Carey has been a trusted advisor to Aurora on a variety of growth initiatives, including our recently successful capital raise,” said Michael Singer, Executive Chairman. “In this new position, Carey will be a core member of Aurora’s senior management team, executing on the development of key strategic initiatives, including partnerships and M&A opportunities. We look forward to working closely with Carey to leverage his extensive knowledge in the execution of our investor development, international growth and partnership strategies, sourcing potential accretive opportunities in the global cannabis industry and negotiating favourable business transactions.”

This followed the news of the filing on Tuesday of a preliminary short-form base shelf prospectus with Canadian securities regulators and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission.  When made effective, this will allow Aurora to issue stock offerings, debt securities, subscription receipts, units or warrants for an aggregate value of up to $750 million during a period of 25 months, according to the company.

Charlotte’s Web Holdings, Inc. (CWBHF) (CWEB), a market share leader in hemp-derived CBD extract products, reported financial results for Q4 and year ended December 31, 2018. Fourth quarter highlights included: retail doors increased over 80% to 3680 and 57% of revenue came from ecommerce, organic consolidated revenue growth of 71% to $21.5 million, and gross profit increased 63% to $16.3 million, or 76% of consolidated revenue. Highlights of 2018 Full Year Results included: organic revenue growth of 74% to $69.5 million, gross profit increased 75% to $52.3 million, and adjusted EBITDA decreased to 30% from 36% of consolidated revenue.

“During the fourth quarter we concentrated our efforts on completing the 2018 harvest and building product inventory to support growing consumer demand. Our 2018 harvest resulted in 675,000 pounds of raw hemp compared to 63,000 pounds in 2017. This inventory build ensures we are able to meet growing demand and supply the large national retail chains that are beginning to carry our products. In general, broader consumer awareness of the benefits of cannabinoids, namely cannabidiol (CBD) from hemp extract, is driving increased uptake in all product categories in our retail channels and e-commerce platform,” stated Hess Moallem, President and CEO.

Charlotte’s Web has been actively adding additional retail distribution customers and locations and recently surpassed 4,000 locations after national retail chains began carrying its products.  Several new products and formats are planned for 2019 in animal nutrition, wellness topicals and human consumables, according to the company.

marijuanastocks.jpeg


This Blog is an affiliate of MIDAM VENTURES LLC.  Midam has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Midam owns zero shares. Click Here For Full Disclaimer

3 Healthcare Stocks That May Keep Your Portfolio Healthy

As medical experts and scientists discover diseases, healthcare companies are ready to tackle these challenges by developing top-quality treatments.   Because of this, the healthcare sector manages to remain above the curve, which in turn leads to growth.  According Deliotte, global health expenditures are forecast to rise as healthcare spending is expected to increase 5.4% annually between 2017-2022, amounting to $10.059 trillion.

healthcarestocks.jpg

“The emergence of personalized medicine, increased use of exponential technologies, entry of disruptive and non-traditional competitors, the demand for expanded care delivery sites, and revamped payment and public funding models are all impacting the financial performance of the health care ecosystem. The health care market is looking to health technology for help.”

With chronic diseases running rampant, the demand for innovative healthcare solutions is rising rapidly.  As healthcare companies are working to develop fresh and innovative approaches, whether it be technology, devices or drugs, several healthcare stocks are beginning to see higher activity in the markets.

Premier Health Group (PHGRF) (PHGI.CN) , focuses on innovative healthcare approaches that combine human skill-based expertise with emerging technologies, announced it has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support (CDS) tool.  This agreement provides Premier Health’s over 4600 physicians using its Juno EMR platform access to the industry’s sole medical cannabis-specific CDS tool, which is designed to include medical cannabis into patient treatment plans and overcome barriers from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy while remaining on a patient-centered basis using clinically-validated data.

“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

This news followed the company’s announcement partnering Bio Conscious Technologies (BCT) to bring their artificial intelligence (AI) technology to Premier Health’s user base for improved monitoring and management of chronic conditions, such as diabetes.  The integration of BCT’s algorithm DiaBits into Premier Health’s patient-centric app can learn an individual’s physiology and with machine learning technology predict where their blood sugar will trend over time based on their past.

AVEO Oncology Inc (AVEO) announced financial results earlier this month for the full year ended December 31, 2018 and a business update. The company reported narrowing its Q4 net loss per share to $0.03, from $0.08 the year prior and saw revenue increase to $1.48 million from the previous year’s $82,000. AVEO stated that it believes that its $24.4 million in cash, cash equivalents, and marketable securities at the end of 2018 combined with the $7.5 million from sales under an agreement with SVB Leerink should allow it to fund planned operations into Q1 2020.

Furthermore, last month the company presented top-line results from the TIVO-3 trial, AVEO’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in 350 subjects with refractory advanced or metastatic renal cell carcinoma at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.

“The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEGF TKIs in the treatment of kidney cancer,” said Michael Bailey, President CEO. “We continue to believe that there is a significant potential commercial opportunity for an active and well tolerated therapy within the third plus line of therapy, particularly one that demonstrated activity in a highly refractory patient population that has received prior PD-1 treatment. We are hopeful that the positive PFS outcomes from TIVO-3 translate into an improved overall survival hazard ratio and look forward to reporting a more mature interim OS outcome in the fourth quarter of 2019.”

Amarin Corporation plc (AMRN) announced that the American Diabetes Association® (ADA) issued important updates to the Standards of Medical Care in Diabetes for 2019 which include updates related to the results of the REDUCE-IT™ cardiovascular outcomes study. The REDUCE-IT related updates were informed by newly published research covering REDUCE-IT results.

The Standards of Care update references the drug, icosapent ethyl, which is studied in Amarin’s REDUCE-IT that evalutes Vascepa® (icosapent ethyl) capsules. Vascepa has been approved for use by the US FDA as an aide to diet to reduce triglyceride levels for severe hypertriglyceridemia. Amarin has begun transmission of data to the FDA to support the submission of a supplemental new drug application to expand Vascepa’s FDA label based on the landmark REDUCE-IT results.

“As we have commenced transmission of data to the FDA for the submission of our sNDA seeking an expansion of the Vascepa label based on the landmark REDUCE-IT results, we are pleased by ADA’s acknowledgement of the importance of the REDUCE-IT results in its 2019 update of the Standards of Care,” said Craig B. Granowitz, M.D., Ph.D., SVP, CMO. “The medical community will also hopefully take note of recent research reporting the prevalence of, and increased costs associated with, diabetes mellitus and high triglyceride levels despite statin therapy5.”

healthcarestocks1.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. Midam owns zero shares of Premier Health Group Inc., which they purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

3 Marijuana Stocks Making Headlines

North America is by far the leader of the cannabis industry, as it is not only the fastest growing region but also possesses the largest market share.  Canada became the first G7 nation to legalize adult-use recreational cannabis and the influx of United States legalizing one form or another of cannabis as well the passing of the 2018 US Farm Bill, which legalized hemp, is driving the growth of the sector. The two countries, together, command the global cannabis industry, which is forecast to hit $146.4 billion across the globe by 2025, with a compound annual growth rate of 34.6%, according to a Grand View Research report.

marijuana.jpg

The increased legalization of cannabis along with the growing utilization in several medical applications are key factors for driving the growth of the industry.   As the cannabis industry continues to evolve, there are several marijuana stocks making headlines.

Leafbuyer Technologies, Inc. (LBUY) announced that the number of Greenlight platform users has reached nearly 80,000, further to its recent release announcing Leafbuyer’s launch of the Greenlight app in Colorado and Oklahoma. The platform permits consumers to order cannabis products ahead, earn loyalty points, and cut the line to pick up and pay at participating dispensaries. Presently, the number of Leafbuyer dispensary clients with capabilities has grown to a total of 60, located throughout the states of California, Colorado, Oklahoma, and Michigan.

“The rapid geographic implementation of the Greenlight technology and the large number of users is encouraging. Developments are under way to bring new features to the platform that are expected to be a catalyst for continued revenue growth,” said Kurt Rossner, CEO of Leafbuyer. “We plan to expand the footprint further and optimize this technology to make it a staple in every legal market across the country.”

This news followed the announcement that Leafbuyer and Greenlight now integrate with Flowhub’s point of sale and compliance technology, giving customers have access to immediate, up-to-date menu information regarding product availability in dispensaries using Flowhub API and Leafbuyer platforms.

Curaleaf Holdings, Inc. (CURLF) (CURA.CN) on its recent earnings conference, company executives said CVS Health Corp (CVS) will start offering its Curaleaf Hemp lotions and transdermal patches in around 800 stores across the U.S. Today the company annouced the opening of its 23rd Florida dispensary as it continues to expand rapidly throughout the state. Curaleaf has the largest cannabis dispensary footprint in the US, now with 43 dispensaries across the country.

“As Curaleaf continues to deliver on its expansion strategy, we are well positioned to improve the quality of patients’ lives by providing access to safe top-quality cannabis products,” shared Joe Lusardi, Curaleaf CEO.

The dispensary includes the community’s first medical marijuana drive-thru. Curaleaf was the first in the state to introduce and test the drive-thru concept at its Palm Harbor dispensary and since has launched a second drive-thru in Orlando.   Today, Curaleaf also announced it will celebrate its grand opening on Thursday, March 21 from 3pm until 7pm at its Gainesville dispensary.

Canopy Growth Corporation (CGC) (WEED) announced it has acquired AgriNextUSA, a hemp enterprise led by CEO Geoff Whaling, to accelerate Canopy Growth’s entry into key American jurisdictions. As previously mentioned, Canopy Growth is on track to build the first Hemp Industrial Park in the Southern Tier of New York State, after receiving a state license to produce and process hemp. Canopy growth committed to invest $100M to $150M into a hemp operation as well as the production of high-quality CBD products.

“The United States is the next stop on Canopy Growth’s desired path to becoming a leading, revenue-generating company focused on all aspects of cannabinoids and their potential,” said Bruce Linton, co-CEO and Chairman. “Our significant investments, acquisitions and compilation of talented leaders such as Geoff will position us for swift expansion throughout the United States. By collaborating with a pioneer like Geoff, who has been involved with our team since our earliest days in 2013, we will aim to turn hemp supplied by American farmers into a wide range of products.”

This news followed Canopy’s announcement earlier this week of a two-year processing and extraction agreement Wednesday with HollyWeed Manufacturing & Extracts Inc.  The agreement entails that HollyWeed will process Canopy-supplied dried cannabis flower in its and in turn, HollyWeed will supply Canopy with oil and resin extracted from the source material. The companies expect the first shipment of product for extraction will take place in fall of 2019.

marijuanastocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018 and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam owns 77,000 shares of Leafbuyer Technologies. Midam may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc. Click here for full Midam disclaimer.

3 Marijuana Stocks To Add To Your Watch-List This Week

The marijuana market has been really budding over the last few years, especially with the recent monumental legislature that has been passed in North America. It seems to be a promising time for marijuana companies. Last year’s legalization of recreational pot in Canada and California, as well as the passing of the 2018 US Farm Bill which legalized hemp, may be setting the stage for more countries and/or states to “go green”.

cannabisstocks.jpg

As we see increased legalization of marijuana, whether medical or recreational, the potential to generate job opportunities and economic benefits rises. According to an Arcview Market Research and BDS Analytics report, consumer spending on legal cannabis is forecast to reach USD $11 billion this year and by 2022 it’s anticipated to surpass USD $23 billion.  Also, during that time period, the U.S. cannabis industry is expected to create over 467,000 full-time equivalent jobs, an 180% increase from 2017’s 170,000 full-time equivalent jobs. As the marijuana industry continues to grow at a rapid rate, there are several marijuana stocks to add to your watch-list.

Leafbuyer Technologies, Inc. (LBUY) announced the official launch of the leading mobile application Greenlight in Colorado and Oklahoma, further to the company’s announcement of the acquisition of Greenlight in November.  Previously, the order ahead app was only available in California and now 16 Leafbuyer dispensary clients in Colorado as well as 9 clients in Oklahoma have signed up. Through the Greenlight app, consumers can preorder their favorite cannabis products from participating dispensaries and skip the line when they go to pay and pick them up.

“In this fast-paced industry, we need to stay ahead of technology and continuously improve our offerings to drive more value to our clients,” said Kurt Rossner, CEO. “Greenlight is one more platform we have that separates us from our competition, inherently making Leafbuyer a more attractive option to dispensary clients nationwide.”

This news followed the announcement that Leafbuyer and its recently acquired mobile app, Greenlight, now integrates with Flowhub’s point of sale and compliance technology.   On both Leafbuyer.com and the Greenlight app, customers now have access to immediate, up-to-date menu information regarding product availability in dispensaries using Flowhub API and Leafbuyer platforms. Recently, the company has also signed over 50 licensed medical dispensaries within the Oklahoma market.

Tilray Inc (TLRY) is scheduled to announce Q4 earnings today March 18th after the closing bell.  The company recently announced the expansion of its global leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy.

Brenden Kennedy, CEO of said, “we’re pleased to welcome Andrew to our senior leadership team to execute strategic transactions that will further accelerate Tilray’s long-term global growth. Andrew shares our commitment to a disciplined, strategic approach in pursuing inorganic growth opportunities.

Last week, Tilray and LiveWell Canada annouced finalizing their agreement for the supply of hemp cannabidiol (CBD) to Tilray. Under the deal, LiveWell will supply Tilray with a monthly quantity of up to 300 kilograms of hemp-derived CBD isolate, or an equivalent amount of full-spectrum CBD extract. It includes an option to increase to 500 kilograms per month. Shipping will begin in Q2.

Aurora Cannabis Inc (ACB) announced last week that it has appointed Nelson Peltz as a Strategic Advisor. Mr. Peltz and Aurora will work collaboratively and strategically to explore potential partnerships that would be the optimal strategic fit for successful entry into each of Aurora’s contemplated market segments and advise on the company’s global expansion strategy.

“Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us,” said Terry Booth. “Like us, Nelson also takes a long-term view of value creation to benefit all stakeholders. We look forward to working with Nelson to further extend our global cannabis industry leadership by aligning Aurora with each of the major market segments cannabis is set to impact.”

This news followed the launch of sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German monograph for in-pharmacy preparation.

marijuanastocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018 and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam owns 77,000 shares of Leafbuyer Technologies. Midam may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc.

 

4 Marijuana Stocks That May Grow Your Portfolio

The global legal marijuana market is forecast to reach USD $146.4 billion by 2025, according to a report by Grand View Research. This growth can be contributed to the rising adoption of marijuana in several medical applications as well as the increased legalization seen around the world. The industry continues to show strength while the sentiment surrounding the stocks of the sector remains positive.

marijuanastocks.jpg

The North American legal marijuana market alone hit $12 billion last year, and analysts forecast that the market will reach $25.5 billion by 2021, according to a report by Cannabis Business Plan.  As the marijuana sector continues to generate growth, investors continue to place their bets on marijuana stocks.

Next Green Wave Holdings (NXGWF) (NGW.CN) announced that it, together with its US subsidiary Crossgate Capital US Holdings Corp. have signed a definitive agreement to acquire 100% of California-based SDC Ventures, LLC. The total value of this transaction is $20.6 million in cash, shares and performance shares to be earned over the next three years.  SDC a premium cannabis consumer products goods, manufacturing and extraction leader, with 8 leading cannabis brands, 45 CBD and THC products and a large network of retail and online sales channels including 700 Zumiez stores which compliments Next Green Wave’s current distribution opportunities.

“The SDC team shares our vision and provides expertise that is synergistic to that of Next Green Wave – to be the number 1 cannabis consumer products goods company in California,” stated Leigh Hughes, CEO. “Not only does this acquisition give us an array of premium brands associated with key world-renowned influencers to penetrate global markets, it also gives us increased distribution with revenues from sales, along with direct to consumer reach, relationships and specialty extraction methods. Having the opportunity to market through strategic brand partners to millions of validated and loyal followers is a big deal when marketing consumer products.”

This news followed the announcement of being granted Conditional Use Permits for nursery and both non-volatile and volatile extraction operations for its 3,240 ft² indoor facility by the City of Coalinga, CA as well as approval for the facility site design allowing for construction preparations to begin. This will enable Next Green Wave to accelerate its seed and seedling production program for its own yield and sales to licensed commercial growers and resellers. Furthermore, the facility will help advance innovative tissue culture research and the development of new high-quality cannabis strains using Intrexon’s (XON) Botticelli™ platform, allowing Next Green Wave to produce and sell seeds or clones that have standardized plant attributes and are pathogen and pesticide free.

Aurora Cannabis Inc (ACB) announced that it has appointed Nelson Peltz as a Strategic Advisor. Mr. Peltz and Aurora will work collaboratively and strategically to explore potential partnerships that would be the optimal strategic fit for successful entry into each of Aurora’s contemplated market segments and advise on the company’s global expansion strategy.

“Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us,” said Terry Booth. “Like us, Nelson also takes a long-term view of value creation to benefit all stakeholders. We look forward to working with Nelson to further extend our global cannabis industry leadership by aligning Aurora with each of the major market segments cannabis is set to impact.”

Earlier this week, Aurora announced that it has commenced sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German monograph for in-pharmacy preparation. Neil Belot, Aurora’s Chief Global Business Development Officer, commented, “having established early mover advantage in selling cannabis oils in Germany, we are exceptionally positioned to extend our market leadership and accelerate the growth of our European operations”

Choom™ (CHOO.CN) (CHOOF) announced that it is entering the United States market, starting with the state of New Jersey, through its wholly owned US subsidiary, Choom Holdings USA Inc., has signed a letter of intent  to purchase an equity interest in a New Jersey based medical retail dispensary applicant in New Jersey’s upcoming Request of Applications that also intends to enter into recreational cannabis retail upon legalization, which is anticipated in 2020.

“This is our first step into the United States, and we are very excited for our partnership with this experienced group to have the Choom Brands in New Jersey.” states Chris Bogart, President & CEO.  “New Jersey is home to over 9 million people currently being served by only 12 cannabis operators in its medical program. New Jersey is an exceptional market to expand the Choom Brands.  We are very impressed with the progress they have achieved to date, and with our expertise in cannabis retail, we are confident we can help them successfully operate in the New Jersey market.”

Choom recently provided an update on its retail development strategy as an emerging consumer cannabis company that has secured one of the largest retail networks in Canada, as well as a $27 million-dollar investment from Aurora Cannabis (ACB). Choom has completed the buildouts of 17 retail locations across Western Canada and has 8 additional retail locations currently under construction.

HEXO Corp (HEXO) and Newstrike Brands Ltd. (TSX-V: HIP) annouced that they have entered into a definitive arrangement agreement under which HEXO will acquire all of Newstrike’s issued and outstanding common shares in an all-share transaction valued at approximately C$263 million.

Under the terms of the Arrangement Agreement, Newstrike shareholders will receive 0.06332 of a HEXO common share in exchange for each Newstrike common share held. The transaction has been unanimously approved by the board of directors of each of HEXO and Newstrike, and Newstrike’s board of directors recommends that its shareholders vote in favor of the Transaction.

“We’re thrilled to welcome the Newstrike team into the HEXO family.  Jay Wilgar (CEO of Newstrike) and his team have built incredible relationships, including teaming up with The Tragically Hip, and they share HEXO’s vision of bringing exceptional branded cannabis experiences to adults everywhere,” said Sebastien St-Louis, CEO and co-founder of HEXO. “With Newstrike, we’re adding talented employees and infrastructure to take HEXO to the next level on our journey to become one of the largest cannabis companies in the world. We’re extremely proud of our record of execution, and today are committing to achieving over $400 million in net revenue in 2020.”

marijuanastockstowatch.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Next Green Wave (NGW), Midam has been paid $150,000 from Next Green Wave (NGW) for a period from October 1, 2018 to November 8, 2018. Midam has been compensated an additional $100,000 and has extended its period of coverage to December 8, 2018. Midam has been compensated an additional $75,000 and has extended its period of coverage to January 8, 2019. Midam has been compensated an additional $50,000 and has extended its period of coverage to February 8, 2019. Midam has been compensated an additional $100,000 and has extended its period of coverage to April 12, 2019. Midam may buy or sell additional shares of (NGW) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Next Green Wave. Click here For Full Disclaimer.